Holdings
F/m Emerald Life Sciences Innovation ETF
As of May 31, 2026, F/m Emerald Life Sciences Innovation ETF reported 38 positions worth US$104M. Largest: Travere Therapeutics, Inc., Cogent Biosciences, Inc. and Livanova Plc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Travere Therapeutics, Inc. | 171K | US$8.05M | +22,171 | May 31, 2026 |
| Cogent Biosciences, Inc. | 226K | US$7.91M | +3,389 | May 31, 2026 |
| Livanova Plc | 101K | US$7.47M | +1,516 | May 31, 2026 |
| Spyre Therapeutics, Inc. | 91,588 | US$6.73M | −6,388 | May 31, 2026 |
| Guardant Health, Inc. | 44,694 | US$5.8M | +667 | May 31, 2026 |
| Mirum Pharmaceuticals, Inc. | 50,911 | US$5.17M | +763 | May 31, 2026 |
| Corcept Therapeutics Incorporated | 72,454 | US$5.03M | +31,859 | May 31, 2026 |
| United Therapeutics Corporation | 7,841 | US$4.37M | −419 | May 31, 2026 |
| Veradermics, Incorporated | 35,568 | US$3.59M | new | May 31, 2026 |
| Savara, Inc. | 651K | US$3.39M | +9,764 | May 31, 2026 |